“…The recent termination of Phase I clinical study on synthetic miR-34a mimic (MRX34) (Beg et al, 2017), owing to high incidence of adverse immune responses, again testifies the body's capability to distinguish chemoengineered RNAi agents as foreign. Therefore, biologic approaches such as in vitro transcription (Beckert and Masquida, 2011) and, especially, bioengineering in live cells (Ponchon and Dardel, 2007;Ponchon et al, 2009;Huang et al, 2013;Li et al, 2014Li et al, , 2015Li et al, , 2018Chen et al, 2015;Wang et al, 2015;Pereira et al, 2016;Fang et al, 2017), are highly warranted to produce natural RNA molecules that should better represent cellular ncRNA properties for basic research and experimental therapy (Ho and Yu, 2016;Pereira et al, 2017).…”